Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma-Reference-Cited by-同舟云学术

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

Published:2014-07-24 Issue:4 Volume:124 Page:536-545
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhu Yuan Xiao¹,Braggio Esteban¹,Shi Chang-Xin¹,Kortuem K. Martin¹,Bruins Laura A.¹,Schmidt Jessica E.¹,Chang Xiu-Bao²,Langlais Paul²,Luo Moulun³,Jedlowski Patrick¹,LaPlant Betsy⁴,Laumann Kristina⁴,Fonseca Rafael¹,Bergsagel P. Leif¹,Mikhael Joseph¹,Lacy Martha⁵,Champion Mia D.¹⁶,Stewart A. Keith¹

Affiliation:

1. Division of Hematology-Oncology and

2. Department of Biochemistry & Molecular Biology, College of Medicine, Mayo Clinic, Scottsdale, AZ;

3. Center for Metabolic and Vascular Biology, Arizona State University, Tempe, AZ;

4. Division of Biomedical Statistics and Informatics and

5. Division of Hematology, Mayo Clinic, Rochester, MN; and

6. Division of Biomedical Statistics and Informatics, Mayo Clinic, Scottsdale, AZ

Abstract

Key Points We identified CRBN-binding proteins and confirmed recent work implicating the Ikaros transcription factors as important members. Low IZKF1 levels predict lack of IMiD responsiveness and shorter OS; IZKF1 expression is a potential predictive biomarker for clinic application.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/4/536/1382115/536.pdf

Reference39 articles.

1. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.;Rajkumar;Am J Hematol,2011

2. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.;Parman;Nat Med,1999

3. Thalidomide is an inhibitor of angiogenesis.;D’Amato;Proc Natl Acad Sci USA,1994

4. Identification of a primary target of thalidomide teratogenicity.;Ito;Science,2010

5. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.;Escoubet-Lozach;Cancer Res,2009

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

2. LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway;Cell Death & Disease;2024-07-18

3. Targeting the ubiquitin pathway in lymphoid malignancies;Cancer Letters;2024-07

4. Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide;British Journal of Haematology;2024-04-29

5. Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode;European Journal of Medicinal Chemistry;2024-04